Different outcomes for relapsed vs. refractory neuroblastoma after therapy with (131)I-metaiodobenzylguanidine ((131)I-MIBG)

BACKGROUND: (131)I-metaiodobenzylguanidine ((131)I-MIBG) is a targeted radiopharmaceutical with significant activity in high-risk relapsed and chemotherapy-refractory neuroblastoma. Our primary aim was to determine if there are differences in response rates to (131)I-MIBG between patients with relap...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Eur J Cancer
Päätekijät: Zhou, Margaret J., Doral, Michelle Y., DuBois, Steven G., Villablanca, Judith G., Yanik, Gregory A., Matthay, Katherine K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2015
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4607645/
https://ncbi.nlm.nih.gov/pubmed/26254811
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejca.2015.07.023
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia